所有产品
  • 抗体
  • 试剂盒
  • 多肽
  • 蛋白
  • 生化试剂
  • 组织芯片
EN
cAMP/ cGMP/ Protein A/ β-Actin/ BSA/ Ddx4/ APOE/ TAU pT181/ TAU pT217/ Tau 1-441/ Aβ1-40/ Aβ1-42/ α-Syn/ GFAP/ IL/ CD/ 标记试剂盒/ GFP/ Flag/ 多肽合成服务/ /
抗体药类似物
当前位置：首页 > 产品中心 > 抗体 > 抗体药类似物
产品中心
Product Center
Research Grade Navicixizumab
All
SEC-HPLC
Bioactivity
SDS-PAGE
  • Catalog： TD-HV571036
  • Clonality： Monoclonal
  • Application： ELISA, Bioactivity: FACS, Functional assay, Research in vivo
  • Synonyms： Bispecific, OMP-305B83, 1638338-43-8
  • 规格：
    询价
  • 价格：
    ¥100ug
定制服务咨询
详细相关信息
FAQ
实验方案
参考文献
  • Catalog No.
    TD-HV571036
  • Description
    Navicixizumab(TD-HV571036) is a research-grade recombinant antibody targetingDelta-like protein 4. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.
  • Species reactivity
    Human
  • Applications
    ELISA, Bioactivity: FACS, Functional assay, Research in vivo
  • Host species
    Humanized
  • Isotype
    IgG2-kappa
  • Clonality
    Monoclonal
  • Target
    Delta-like protein 4, Drosophila Delta homolog 4, Delta4, DLL4, Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A
  • Endotoxin level
    Please contact the lab for this information.
  • Purity
    >95% purity as determined by SDS-PAGE.
  • Purification
    Protein A/G purified from cell culture supernatant.
  • Accession
    Q9NR61 & P15692
  • Form
    Liquid
  • Storage buffer
    0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
  • Stability and Storage
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
  • Alternate Names
    Bispecific, OMP-305B83, 1638338-43-8
  • Background
    Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways. Here, we present safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy data from a phase I study (trial registration ID: NCT01946074) of dilpacimab in patients with advanced solid tumors. Eligible patients (≥18 years) received dilpacimab intravenously on days 1 and 15 in 28-day cycles at escalating dose levels (range, 1.25–7.5 mg/kg) until progressive disease or unacceptable toxicity.
  • Caption
    SEC-HPLC detection for Research Grade Navicixizumab.　　|　Detects DLL4 in indirect ELISAs.　　|　SDS-PAGE for Research Grade Navicixizumab
  • Note
    For research use only. Not suitable for clinical or therapeutic use.